Search Results for "Adriamycin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Adriamycin. Results 21 to 30 of 34 total matches.
See also: doxorubicin

Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004  (Issue 1179)
1179) March 29, 2004 orubicin (Adriamycin, and others), cyclophosphamide (Cytoxan, and others ...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and...
Med Lett Drugs Ther. 2004 Mar 29;46(1179):27-8 |  Show IntroductionHide Introduction

Ixabepilone (Ixempra) for Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008  (Issue 1278)
or metastatic breast cancer after failure of an anthracycline such as doxorubicin (Adriamycin) and a taxane ...
Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine (Xeloda - Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin (Adriamycin) and a taxane such as paclitaxel (Taxol, and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have...
Med Lett Drugs Ther. 2008 Jan 28;50(1278):7-8 |  Show IntroductionHide Introduction

Hyperbaric Oxygen Therapy for Refractory Wounds

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
such as doxorubicin (Adriamycin, and others) or cisplatin (Platinol, and others). Reversible myopia ...
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
Med Lett Drugs Ther. 2010 Mar 8;52(1333):19-20 |  Show IntroductionHide Introduction

Azacitidine (Vidaza) for Myelodysplastic Syndrome

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005  (Issue 1201)
(Adriamycin, and others), induce a complete response in a minority of patients; the average duration ...
Azacitidine (Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly synthesized DNA and inhibits DNA methyltransferase. Hypomethylation of DNA can restore the normal expression of genes critical for cell differentiation.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):11 |  Show IntroductionHide Introduction

Drugs for Vomiting Caused by Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
, others) Doxorubicin (Adriamycin, others) Hydroxyurea (Hydrea) Idarubicin (Idamycin) Melphalan (Alkeran ...
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Med Lett Drugs Ther. 1993 Dec 24;35(912):124-6 |  Show IntroductionHide Introduction

Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003  (Issue 1158)
(Adriamycin*), erythromycin, etoposide (Vepesid), fexofenadine (Allegra), hydrocortisone, indinavir ...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 |  Show IntroductionHide Introduction

Coenzyme Q10

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
(Adriamycin, and others) may prevent or reduce anthracycline-induced cardiomyopathy. 14 CoQ10 ...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Med Lett Drugs Ther. 2006 Feb 27;48(1229):19-20 |  Show IntroductionHide Introduction

Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
Daunorubicin5 (Cerubidine)3 Alemtuzumab (Campath) Doxorubicin5 (Adriamycin)3 Bendamustine (Treanda ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK1) receptor antagonist netupitant and the serotonin-3 (5-HT3) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK1 receptor antagonist to be...
Med Lett Drugs Ther. 2015 Apr 27;57(1467):61-3 |  Show IntroductionHide Introduction

Drugs for Breast Cancer

   
Treatment Guidelines from The Medical Letter • Jan 01, 2005  (Issue 29)
Line Second line Doxorubicin 60-75 mg/m 2 IV (d1) q21days 36% – 50% 30% (Adriamycin, and others ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Treat Guidel Med Lett. 2005 Jan;3(29):1-6 |  Show IntroductionHide Introduction

Bevacizumab (Avastin) for Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008  (Issue 1287)
Adriamycin 2008 Epirubicin HER2 Xeloda volume 50 trastuzumab Taxotere Taxol Page 42 paclitaxel metastatic ...
Bevacizumab (Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel (Taxol, and others) for first-line treatment of...
Med Lett Drugs Ther. 2008 Jun 2;50(1287):42-3 |  Show IntroductionHide Introduction